Methylprednisolone Acetate Injection Shortage: Current Availability and Manufacturer Updates
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA reports an ongoing shortage of Methylprednisolone Acetate Injection, a medication used in rheumatology, with supply levels varying significantly across major manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Methylprednisolone Acetate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Methylprednisolone Acetate Injection, a medication primarily used within the therapeutic category of rheumatology, is currently listed as being in shortage. The shortage affects multiple strengths, specifically the 40 mg/1 mL and 80 mg/1 mL presentations. This shortage status was first posted on December 15, 2021, and was most recently updated on February 9, 2026.
Which Manufacturers Are Affected
Several manufacturers are currently experiencing supply issues, while others maintain limited or full inventory:
- Amneal Pharmaceuticals (866-525-7270):
- 80 mg/1 mL (NDC 70121-1574-5): Available; 2 to 4 weeks of inventory based on demand. Next supply expected week of February 9, 2026.
- 80 mg/1 mL (NDC 70121-1574-1): Available; 4 to 8 weeks of inventory. Next supply expected week of March 16, 2026.
- 40 mg/1 mL (NDC 70121-1573-5): Available, but currently under backorder due to demand. Next supply expected week of February 9, 2026.
- 40 mg/1 mL (NDC 70121-1573-1): Limited Availability; 4 to 6 weeks of inventory. Next supply expected week of February 9, 2026.
- Sagent Pharmaceuticals (866-625-1618):
- 40 mg/1 mL (NDC 25021-820-10) and 80 mg/1 mL (NDC 25021-821-05): Available.
- 40 mg/1 mL (NDC 25021-820-05): Limited Availability; estimated availability May 2026.
- Eugia US LLC (888-238-7880):
- 40 mg/1 mL and 80 mg/1 mL: Unavailable. Currently on backorder with a recovery date to be determined. Patients and providers are advised to check wholesalers for inventory.
- Par Health, USA LLC (800-828-9393):
- 80 mg/1 mL (NDC 42023-240-01): Unavailable.
Why There's a Shortage
The source data does not provide a specific underlying cause for the shortage, though some manufacturers note that current inventory levels are being impacted by high demand.
What Patients Should Do
If you rely on Methylprednisolone Acetate Injection for your treatment, please consider the following steps:
- Consult Your Healthcare Provider: Speak with your doctor regarding your treatment plan and potential alternatives if your specific dosage is unavailable.
- Speak with Your Pharmacist: Pharmacists may have information on local stock or may be able to source the medication from different wholesalers.
- Contact Manufacturers: You may use the contact information provided above to inquire about the most recent availability updates for specific NDCs.
Disclaimer: Patients should always consult with their healthcare provider or pharmacist for medical advice and before making any changes to their medication regimen.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category